Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090610 · ClinicalTrials.gov registry record · Phase 2
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00090610 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 150 participants.
The verdict
NCT00090610, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the progression-free survival of two treatment regimens for relapsed ovarian cancer.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090610
The ClinicalTrials.gov registry entry for NCT00090610 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT00090610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090610 about?
NCT00090610 is a clinical study titled "Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer". The purpose of this study is to compare the progression-free survival of two treatment regimens for relapsed ovarian cancer.
What is the current status of trial NCT00090610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2003-10. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00090610?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG).
Who is sponsoring clinical trial NCT00090610?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.